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Abstract 
 
MicroRNAs are intrinsic regulators of gene expression, apparent in all major cellular 
pathways from differentiation to apoptosis. By targeting complementary mRNA, 
microRNA can direct post-transcriptional downregulation of gene-expression and 
fine tune levels of protein expression. Disruption to microRNAs on a global or 
singular scale has been linked to many diseases and cancers due to reduced genetic 
regulation. 
The biogenesis pathway of microRNAs is well documented, however the functions of 
proteins such as the DICER co-factors TRBP and PACT are not yet fully understood. 
Within this project, these two proteins were investigated in the context of microRNA 
biogenesis, with exploration into novel links to cellular immunity, with a focus on the 
immune checkpoint PD-L1. It is known that PD-L1 is directly regulated by microRNAs 
and has also been shown to be upregulated during dsRNA stress. 
The roles of TRBP and PACT were scrutinized through transient protein knockdown, 
where the impact of their depletion on selected microRNAs and PD-L1 was assessed 
through RT-qPCR and western blot. Endogenous interaction of TRBP and PACT was 
discovered within three different human cancer cell lines, where concurrent 
depletion of these DICER co-factors resulted in disrupted biogenesis of selected 
ubiquitous microRNAs. 
Both TRBP and PACT function in microRNA biogenesis, and PACT was also identified 
as a possible influencer of PD-L1 expression. Potential cross talk between miRNA 
biogenesis and immunity is further discussed through association with Protein Kinase 
R (PKR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Contents 
Abstract ............................................................................................................................ 2 
List of Figures .................................................................................................................. 6 
List of Tables ................................................................................................................... 8 
Acknowledgements ........................................................................................................ 9 
Declaration ..................................................................................................................... 10 
1.0 Introduction ............................................................................................................. 11 
1.1 MicroRNAs and their biogenesis.............................................................................. 11 
1.2 TRBP and PACT are structural homologs .............................................................. 15 
1.3 DICER co-factors in microRNA biogenesis ............................................................ 17 
1.3.1 DICER cleavage ................................................................................................. 17 
1.3.2 TRBP presents substrates to DICER for processing ........................................ 18 
1.3.3 Strand selection ................................................................................................ 19 
1.4 TRBP and PACT participate in viral infection and regulation of the stress 
response........................................................................................................................... 20 
1.5 MicroRNAs in immunity ......................................................................................... 21 
1.5.1 PD-L1 .................................................................................................................22 
1.6 Rationale for use of different cell lines ................................................................. 24 
1.7 Project aims and hypothesis .................................................................................. 26 
2.0 Materials and Methods .......................................................................................... 27 
2.1 Mammalian Cell Culture.........................................................................................27 
2.2 RNA interference ....................................................................................................27 
2.3 RNA isolation ..........................................................................................................27 
2.4 RT-qPCR ................................................................................................................ 28 
2.4.1 Reverse transcription / cDNA synthesis ........................................................ 28 
2.4.2 qPCR  ............................................................................................................... 28 
 2.4.2.1 Primer Design .......................................................................................... 29 
 2.4.2.2 qPCR method .......................................................................................... 29 
4 
 
2.5 MicroRNA RT-qPCR .............................................................................................. 30 
2.5.1 MicroRNA reverse transcription / cDNA synthesis ........................................ 31 
2.5.2 MicroRNA qPCR .............................................................................................. 31 
2.6 Western blot .......................................................................................................... 30 
2.6.1 Sample collection ............................................................................................ 30 
2.6.2 Protein quantification .................................................................................... 30 
2.6.3 Gel, transfer and antibody incubations .......................................................... 31 
2.6.4 Western blot quantification............................................................................ 32 
2.7 CRISPR / Cas9 Genome Editing ............................................................................. 32 
2.7.1 gRNA ................................................................................................................. 32 
2.7.2 Liposomal delivery .......................................................................................... 34 
2.7.3 Puromycin kill curve(s) .................................................................................. 34 
2.7.4 Transfection Efficiency .................................................................................... 35 
2.7.5 Cell sorting ....................................................................................................... 35 
2.7.6 Lentiviral production and delivery ................................................................. 35 
2.7.6.1 Plasmid transformation and isolation .................................................... 36 
2.7.6.2 Lentivirus assembly and harvest ............................................................ 36 
2.7.6.3 Infection ................................................................................................... 37 
2.8 Co-Immunoprecipitation Assay ............................................................................. 37 
    2.9 Statistics  ................................................................................................................ 38 
3.0 Results ...................................................................................................................... 39 
3.1 DICER co-factors TRBP and PACT do not regulate one another ......................... 39 
3.2 Individual knockdown of TRBP or PACT does not affect miRNA abundance .... 41 
3.3 Depletion of both TRBP and PACT leads to downregulation of ubiquitous 
microRNAs .................................................................................................................. 44 
3.4 PACT depletion leads to upregulation of PD-L1 in breast cancer cells ............... 46 
3.5 TRBP and PACT interact endogenously  .............................................................. 50 
3.6 CRISPR / CAS9 Genome Editing ........................................................................... 52 
5 
 
4.0 Discussion ............................................................................................................... 59 
4.1 Depletion of TRBP and PACT is required for suppression of miRNA expression 
in cancer cells  ............................................................................................................. 59 
4.2 TRBP and PACT interact endogenously  .............................................................. 62 
4.3 PACT depletion within breast cancer cells results in upregulation of PD-L1 ..... 64 
4.4 Future work ........................................................................................................... 67 
5.0 Conclusion ............................................................................................................... 68 
6.0 Appendices ................................................................................................................. i 
6.1 Table of solutions ...................................................................................................... i 
6.2 Product links .......................................................................................................... iii 
Abbreviations List ............................................................................................................ iii 
References ......................................................................................................................... v 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
List of Figures 
Figure 1: The microRNA biogenesis pathway ................................................................ 14 
Figure 2: TRBP and PACT domain structure ................................................................. 16 
Figure 3: Dicer domains functional in miRNA processing ............................................ 17 
Figure 4: Altered DICER cleavage sites in the absence of TRBP ................................... 18  
Figure 5: Suppression of T-cell activation during PD-1, PD-L1 interaction .................. 23 
Figure 6: Cellular PKR interactions ............................................................................... 24 
Figure 7: TRBP crRNA target sites ................................................................................. 33 
Figure 8: Liposomal delivery of gene editing components .......................................... 34 
Figure 9: Demonstration of sequential gating for flow cytometry ............................... 35 
Figure 10: Custom primer efficiencies .......................................................................... 39 
Figure 11: TRBP, PACT and DICER mRNA levels post treatment with siRNA against 
TRBP, PACT or DICER .................................................................................................... 40 
Figure 12: Western blot analysis of TRBP and PACT confirming protein knockdown 41 
Figure 13: MiR-16 and miR-21 are ubiquitously expressed in HeLa, RCC4 and MDA231 
cells .................................................................................................................................. 42 
Figure 14: RT-qPCR analysis of miRNAs following independent knockdown of DICER 
cofactors ...........................................................................................................................43 
Figure 15: RT-qPCR analysis of ubiquitous miRNAs following dual knockdown of 
TRBP and PACT .............................................................................................................. 44 
Figure 16: RT-qPCR analysis of miR-155 and miR-221 following dual knockdown of 
TRBP and PACT .............................................................................................................. 45 
Figure 17: PD-L1 mRNA following knockdown of DICER cofactors ............................ 47 
Figure 18: Western blot analysis of non-stimulated (NS) and IFN-γ stimulated cells 
following transient knockdown of TRBP and PACT ..................................................... 49 
Figure 19: Western blot quantification of NS and IFN-γ stimulated cells post 
treatment with siTRBP and/or siPACT  ......................................................................... 50 
Figure 20: TRBP and PACT co-immunoprecipitation ................................................... 51 
Figure 21: Puromycin / Alamar blue cell survival assay ................................................ 53 
7 
 
Figure 22: mKate2 fluorescence shift in transfected HeLa and RCC4 cell lines ........... 55 
Figure 23: Transfection efficiency of an MKate 2 plasmid into HeLa and RCC4 cell 
lines ................................................................................................................................. 56 
Figure 24: Western blot analysis of Cas9 transfected MDA-MB-231 cells .................... 57 
Figure 25: Synopsis of PACT depletion of PKR and subsequently translation ............ 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
List of Tables 
Table 1: qPCR primer sequences ................................................................................... 29 
Table 2: Antibodies list ................................................................................................... 31 
Table 3: Guide RNA sequences ....................................................................................... 33  
Table 4: Lentiviral plasmids ........................................................................................... 36 
Table 5: mKate HeLa cell sort ........................................................................................ 56 
Table 6: Solutions.............................................................................................................. i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
Acknowledgements 
 
I would like to thank my supervisor Dr Dimitris Lagos for his expertise and guidance 
throughout this project, and my thesis advisor Dr Michael Plevin for his words of 
wisdom. 
  
I would also like to thank the various members of the Lagos laboratory for their 
encouragement, advice and good spirits, all of whom created a pleasant and inspiring 
work environment. 
 
Finally, I would like to thank my friends and family for their consistent support and 
kindness. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
Declaration 
 
I declare that this thesis is a presentation of original work and I am the sole author. 
This work has not previously been presented for an award at this, or any other, 
university. All sources are acknowledged as references. 
 
  
11 
 
1. Introduction 
1.1 MicroRNAs and their biogenesis 
MicroRNA (miRNA / miR) are short, non-coding RNA (ncRNA) that post-
transcriptionally down-regulate gene expression through association with Argonaute 
proteins and targeting of complementary messenger RNA (mRNA). They function to 
fine tune gene expression, adding an extra layer of control further to the complex 
signalling mechanisms mediating transcription and translation. There are more than 
1917 miRNA sequences identified in Homo sapiens to date, regulating cellular 
processes from differentiation to apoptisis (miRbase, 2018). Moreover, microRNAs are 
degenerate, meaning that one miRNA can have multiple mRNA targets, and one 
mRNA can be targeted by multiple miRNAs (Yi and Fuchs, 2011). 
In mammalians, canonical miRNA are generated through the miRNA biogenesis 
pathway shown in figure 1. They are endogenously coded, transcribed from both 
protein coding and non-coding regions of the genome in cis or in trans with their 
target mRNA (Cai et al., 2009). This means that some microRNAs are transcribed at 
the same time as their target pre-mRNA, through shared promoters or laying in 
intronic locations. On the other hand, some microRNA genes are located far from 
their target mRNA and are independently transcribed (Cai et al., 2009). 
MicroRNA transcription is carried out by RNA polymerase II (Pol II), releasing a 
primary miRNA transcript (pri-miRNA). (Ha and Kim, 2014; Cai et al., 2009), which 
self-complements to form a mismatched hairpin structure, containing a poly(A) tail 
and 5’ cap.  
Within the nucleus, pri-miRNA is cleaved by a microprocessor complex containing 
Drosha, an RNase III endonuclease (Lee et al., 2003), and DGCR8 (DiGeorge 
syndrome critical region 8), a double-stranded RNA-binding protein (dsRBP) (Han et 
al., 2004). This complex releases a 60-70nt precursor microRNA (pre-miRNA) 
transcript which is transported out of the nucleus and into the cytoplasm by exportin 
5 (Lund et al., 2004). Here, the pre-miRNA is processed by the endonuclease DICER 
and cofactors TRBP or PACT, cleaving the terminal loop from the miRNA transcript 
and releasing a mature 22-25nt RNA duplex, with 2nt3’ overhangs (Kim et al., 2016). 
One strand of this RNA duplex, deemed the guide strand, is loaded onto an 
Argonaute (AGO) protein, forming the RNA induced silencing complex, or RISC 
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(Martinez et al., 2002; Ha and Kim, 2014; Noland and Doudna, 2013). The guide strand 
then directs the RISC to complementary mRNA, leading to translational repression by 
mRNA cleavage, degradation or translational inhibition (Ha and Kim, 2014). Only 
AGO2 has the capacity to cleave mRNA, whilst association with AGO 1, 3 and 4 will 
preferentially lead to mRNA degradation or inhibition (Liu et al., 2004; Ha and Kim, 
2014). MicroRNAs have also been linked with epigenetic regulation, forming a 
feedback loop in which miRNAs can remodel chromatin and reduce rates of gene 
transcription (Tao et al., 2017). 
Dysregulation of miRNA biogenesis leading to impairments in mature miRNAs is 
linked to many cancers. For example, defects in exportin 5 can lead to accumulation 
of pre-miRNAs in the nucleus and a global downregulation of mature miRNAs (Sun et 
al., 2016). This has been associated with colon, gastric and endometrial tumours 
(Melo et al., 2010). Partial loss of function of DICER is also associated with human 
cancers, including breast, kidney, lung, ovary and stomach (Kumar et al., 2009). This 
is thought to be due to a global down-regulation of miRNAs and hence reduced 
regulation of global gene expression, or more specifically over or under expression of 
oncomiRs and tumour suppressor miRs.  
OncomiRs, or oncogenic microRNAs, target mRNA transcripts from tumour 
suppressor genes (Oliveto et al., 2017). Involved in genomic integrity and cell cycle 
checkpoints, tumour suppressor genes help prevent uncontrolled cellular growth 
associated with cancer (Lee and Muller, 2010). Tumour suppressor microRNAs target 
transcripts of oncogenes (Oliveto et al., 2017), which promote cell growth, division 
and survival (Lee and Muller, 2010). Dysregulation to oncomiRs and/or tumour 
suppressor miRs reduce genetic regulation of the genes associated with cancer, 
increasing the likelihood of cancer development. This effect can also be caused by 
Drosha mutations (Hato and Kashima, 2017). 
Aside from canonical microRNA biogenesis as detailed above, some microRNAs can 
also be formed non-canonically, or in a way that deviates from the ‘norm’ / generally 
known rules. Non-canonical microRNA biogenesis may involve DICER, DROSHA and 
Exportin-5 independent pathways, as reviewed by Ha and Kim (2014). 
This project investigated how cancer cells respond to the depletion of two DICER 
cofactors, transactivation response (TAR) RNA-binding protein (TRBP) and Protein 
Activator of PKR (protein kinase R) (PACT). We aimed to identify if depletion of 
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these cofactors has a negative impact on miRNA biogenesis and thus enhance 
knowledge of emerging trends linking their dysregulation with cancers (Daniels and 
Gatignol, 2012). 
14 
 
Figure 1: The microRNA biogenesis pathway 
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1.2 TRBP and PACT are structural homologs 
TRBP and PACT are double-stranded RNA-binding proteins (dsRBPs) that share 
structural homology. Both proteins are constructed of three domains, with each 
following an αβββα fold as shown in figure 2 (Heyam et al., 2015).  
Domains 1 and 2 of TRBP and PACT are type A double-stranded RNA binding 
domains (dsRBDs) and exhibit conservation of three key regions essential for the 
binding of dsRNA. These are found in the first α-helix, between β1 – β2, and in the 
final α-helix. These have a high affinity for dsRNA interactions in comparison to their 
counterpart, type B dsRBDs (Fierro-Monti and Mathews, 2000), with a particular 
emphasis on the conservation of basic amino acids in RNA binding regions 1 and 2 
that are not found in type B dsRBDs (Heyam et al., 2015). 
Domain 3 of both proteins is a type B dsRBD; though this shares the same structure as 
type A domains, it lacks the residues required for RNA binding (Banerjee and 
Barraud, 2014; Heyam et al., 2015). Instead, this domain provides the interface for 
interaction with other proteins including DICER, themselves and each other (Daniels 
et al., 2009, Heyam et al., 2017). dsRBD3 may also be responsible for binding of 
Argonaute proteins; immunoprecipitation assays have confirmed interaction of TRBP 
and AGO2 (Chendrimada et al., 2005), yet the interface for this interaction is yet to be 
confirmed.
16 
 
Figure 2: TRBP and PACT share structural homology with identical domain arrangement. They exhibit conservation of key amino acids for binding RNA, at the same 
locus. Domains are connected through unstructured linker regions that allow a degree of flexibility and movement. Based on data from Heyam et al., 2015. 
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1.3 DICER co-factors in microRNA biogenesis 
Both TRBP and PACT bind DICER and Argonaute proteins (Haase et al., 2005; Lee et 
al., 2006) and are believed to act as co-factors in the microRNA biogenesis pathway, 
though their exact functions are not fully understood. Through a range of in vitro and 
in vivo experiments, several potential cellular functions have been elucidated for these 
two dsRBPs. 
1.3.1 DICER cleavage 
Firstly, Kim et al. (2014) and Lee et al. (2013) have shown TRBP and PACT to be non-
redundant proteins despite their structural homology and similar molecular 
interactions. TRBP, but not PACT, is able to alter the DICER cleavage site of a subset 
of microRNAs to form isomiRs. This has been shown endogenously, through gene 
knockout experimentation (Kim et al., 2014), and through in vitro reconstitution (Lee 
et al., 2013; Lee and Doudna, 2012). However, to explain this, we first need to 
understand how DICER cleaves microRNAs. 
DICER protein is comprised of eleven domains, 
though the function of one of these domains 
remains unknown (Liu et al., 2018). Figure 3 
illustrates a simplified diagram of DICER, displaying 
the four main domain classes.  
The helicase region at the base of DICER 
accommodates three different helicase domains (Lau 
et al., 2012). These bind the terminal loop of pre-
miRNAs and also form the interface for interaction 
with proteins such as TRBP and PACT (Lee et al., 
2006, Wilson et al., 2015). There is evidence to 
suggest that these helicase domains, particularly the 
DExH box domain, participate in the processing of 
thermodynamically unstable short hairpin RNA 
structures (Soifer et al., 2008). 
The Piwi, Argonaute, Zwille, or ‘PAZ’ (Song and Rossi, 2017) domain, is responsible for 
recognition of substrates; for miRNAs this is a 2nt 3’ overhang on the pre-miRNA 
duplex (Park et al., 2011; Liu et al, 2018) The PAZ domain has two adjacent ‘pockets’ 
Figure 3: Illustration of DICER 
domains functional in miRNA 
processing. Described in text 
adjacent. 
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for binding of short RNAs: a 2nt 3’ overhang binding pocket, and also a phosphate 
binding pocket (Tian et al., 2014). Pre-miRNAs, like most RNAs, have a 5’ phosphate 
group, and hence this structure may determine orientation of loading onto DICER. 
The dsRBD, or double-strand RNA binding domain, binds the 
stem of pre-miRNAs, and is suggested to play a ‘supporting role’ to 
the RNase domains (Kurzynska-Kokorniak et al., 2015). The RNase 
III region, compromising of RNase IIIa and RNase IIIb domains 
(Lau et al., 2012), performs the endonuclease activity and cleaves 
pre-miRNA to produce a mature miRNA duplex. This region acts 
as a molecular ruler, with the distance between the PAZ domain 
and the farthest end of the RNase III domains determining the 
cleavage site of the pre-miRNA (MacRae et al., 2006; Lau et al., 
2012). For human DICER, this is 65 angstroms and equates to 
roughly 25 nucleotides (MacRae et al., 2006).  
TRBP is thought to influence cleavage site, not by altering DICER conformation, but 
by influencing base mismatches in the pre-miRNA stem (Zhu et al., 2018). An 
illustration of this is shown in figure 4. TRBP directly binds and ‘smooths out’ bulges 
in the pre-miRNA stem, reducing the number of nucleotides able to fit in the 65-
angstrom gap, producing truncated miRs as compared to independent DICER 
processing. This can alter miR target sequences: miRNA require perfect 
complementarity of a seed sequence (up to 8 nt), and partial complementarity for the 
remaining 18 nt (Lewis et al., 2003). This seed sequence is found at the 5’ end of the 
mature miRNA (Lewis et al., 2003; Kehl et al., 2017), and even 1 nt change in cleavage 
site is able to shift this sequence and alter the miRNA target.  
We do not directly investigate DICER cleavage site in this study due to multiple 
complementary studies (mentioned above) agreeing that TRBP, but not PACT, can 
alter DICER cleavage sites.  
1.3.2 TRBP presents substrates to DICER for processing 
As previously mentioned, the PAZ domain of DICER recognises pre-miRNA 
substrates. However, it is suggested that TRBP can also contribute to this process. It 
has been shown in vitro that TRBP is able to help DICER differentiate between RNA 
Figure 4: Altered 
DICER cleavage 
sites in the absence 
or presence of TRBP 
via ‘smoothing’ of 
base-pair 
mismatches. 
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substrates (Fareh et al., 2016, Lee and Doudna, 2012), thus creating a quicker and 
more efficient processing rate. 
TRBPs three domains are connected via unstructured linker regions (Heyam et al., 
2015) that allow movement between each domain. Fareh et al. proposes that TRBP has 
an arm-like mechanism, where domain three binds the helicase domain of DICER, 
and domains 1 and 2 bind the RNA substrate. TRBP then presents the RNA substrate 
in an optimum orientation to the PAZ domain of DICER, where a 2nt3’ overhang is 
either detected and the RNA substrate is loaded onto DICER, or the RNA is released 
without entering the longer binding mode. Fareh et al. (2016) did not investigate 
PACT alongside TRBP in their study due to a lack of funding. It would be beneficial to 
also investigate PACT in this manner. 
Contradicting these findings, Kim et al. (2014) found no reduction in microRNA 
abundance upon the production of TRBP or PACT knockout HeLa cell lines. They 
also found no cellular compensation for a reduction in processing efficiency by 
upregulation of DICER, suggesting that neither TRBP or PACT were affecting DICER 
processing efficiency. 
Within this study, we assess transient knockdown of TRBP and/or PACT, with the 
hypothesis that this will give cells less time to compensate for their loss of function 
and we may observe similar phenomenon as seen in vitro. We also explore three 
different cell lines, expanding on HeLa cells which have been the basis for 
investigating endogenous interactions of these two proteins. Due to the age and 
passage number of the HeLa cell line, accumulation of many mutations is extremely 
likely, and thus these cells may no longer constitute a reliable representative model. 
1.3.3 Strand selection 
TRBP and PACT both have the potential to indirectly influence strand selection and 
loading of mature miRNA from DICER to Argonaute proteins by favourably binding 
the more thermodynamically stable end of the miRNA duplex, presenting the least 
stable end to Argonaute for unwinding and loading (Noland and Doudna, 2013, Lee 
and Doudna, 2012). Intriguingly, during in vitro reconstitution, this selection and 
subsequent mRNA targeting was most enhanced in the presence of PACT, and 
sometimes diminished in the presence of TRBP.  
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Alternate strand selection would give rise to different miRNAs with new target 
repertoires. Endogenous assays conducted by Kim et al. (2014) found no evidence of 
this, and again has suggested that neither TRBP or PACT play a role in strand 
selection at least in HeLa cells. Again, we expand on these observations within this 
project through assessment of selected microRNAs, aiming to bridge the gap and 
controversy between in vitro and in vivo experimentation. 
1.4 TRBP and PACT participate in viral infection and regulation of 
the stress response 
Outside of miRNA biogenesis, TRBP and PACT both interact with protein kinase R 
(PKR) as part of the viral defence system, the integrative stress response (ISR) and 
pro-inflammatory pathways (Patel et al., 2000; Garcia et al., 2006; Dabo and Meurs 
2012). PACT is rapidly phosphorylated in stress environments such as viral infection; 
this in turn activates PKR (Patel et al., 2000). TRBP has the opposite effect, and 
instead is a PKR inhibitor (Singh et al., 2011).  
Other activators of PKR include dsRNA of >30bp (Lemaire et al., 2008). Activation of 
PKR by dsRNA follows a bell-curve distribution, where low concentrations of dsRNA 
results in low PKR activation, and high dsRNA concentrations are inhibitory. One 
theory for this result is the ratio of PKR monomers per dsRNA strand. PKR dimerises 
during the activation stages, hence high dsRNA concentrations reduce the probability 
that >1 PKR unit will be associated with the same dsRNA strand, and reduce 
probability of dimerization (Lemaire et al., 2008). 
Upon activation, PKR dimerises, self-phosphorylates and in turn phosphorylates 
eIF2α, a.k.a. the alpha unit of eukaryotic initiation factor 2. EIF2α is required for 
initiation of translation, being responsible for the recruitment of methionine linked 
tRNA to the ribosome (Gale et al., 2000). Upon complete phosphorylation, protein 
translation is inhibited (Patel and Sen, 1998). This constitutes a major defence against 
viral infection, preventing synthesis of viral particles and spread of infection.  
Aside from PKR inhibition of eIF2α, activated PKR can also trigger an influx of 
inflammatory cytokines through activation of NF-ĸB (nuclear factor kappa-light-
chain-enhancer of activated B cells) and thus actively participates in the regulation of 
the inflammasome (Lu et al., 2012). 
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However, as with most cellular processes, the activities of PKR and eIF2α are not so 
black and white. Rather than an on-off switch, activation and inhibition of this 
pathway is comparable to a sliding scale that affects rate of translation. PKR has been 
identified as a potential tumour suppressor through the reduction of protein 
translation and by association, promotion of apoptosis. Evidence of this has been 
shown within mouse models, where upregulation of PKR has an inhibitory effect on 
leiomyosarcoma growth, a type of soft tissue tumour (Vorburger et al., 2005). 
Conversely, loss of protein expression or aberrant expression has been identified in 
leukaemia (Blalock et al., 2010), suggesting that dysregulation rather than simply gain 
or loss of function of PKR activities, is linked to tumours, cancers and other diseases. 
1.5 MicroRNAs in Immunity 
As intricate regulators of gene expression, microRNAs are involved in most 
developmental and pathological processes in the human body. Consequently, their 
dysregulation is tightly associated with cancer and disease. With the degenerate 
nature of these small regulatory molecules, dysregulation of a singular miRNA can 
affect expression of a variety of mRNAs across different cellular pathways. 
A subset of microRNAs have been identified as onco-miRs, classified as such due to 
their dysregulation in most cancers. Examples include miR-21, miR-16, miR-143 and 
let-7 family members (Esquela-Kerscher and Slack, 2006; Yan et al., 2011; 
Kumarswamy et al., 2011; Buscagalia and Li, 2011). 
MiR-21 is a canonical microRNA that is over expressed in most cancers, ranging from 
epithelial to neurological, and has hence been termed a ubiquitous oncogene 
(Buscagalia and Li, 2011). Predicted to have as many as 384 mRNA targets 
(Targetscan.org, 2018), miR-21 functions in diverse cellular roles from embryonic 
development to cell proliferation to apoptosis (Kumarswarmy et al., 2011; Buscagalia 
and Li, 2011). As a regulator of several highly important cellular pathways, disruption 
to the abundance or sequence of miR-21 can lead to serious repercussions, such 
increased cell proliferation or prevention of apoptosis, which are hallmarks of cancer. 
MiR-16 on the other hand, although also a highly conserved and ubiquitously 
expressed canonical miRNA, is frequently deleted or downregulated in a subset of 
cancers (Calin et al., 2002; Bonci et al., 2008; Bandi et al., 2009). MiR-16 functions in 
cellular roles such as promotion of apoptosis, inhibition of proliferation and 
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suppression of tumourigenicity through association with oncogenes such as BCL2 
(reviewd by Aqeilan, et al., 2010). BCL2 is an inhibitor of apoptosis / promoter of cell 
survival and is frequently overexpressed in tumours (Adams and Cory, 2007; Aqeilan 
et al., 2010). Depletion of miR-16 reduces regulation of such oncogenes and may 
increase the likelihood of cancer development. 
Such examples demonstrate how dysregulation of a singular microRNA can lead to 
major ramifications, as miRs are associated with many mRNAs and many molecular 
pathways and as such are critical to cellular health. This knowledge has inspired the 
question: does microRNA machinery itself play a role in cellular immunity? 
MiRNA biogenesis components DROSHA, DICER and AGO have already been linked 
to disease through global downregulation of microRNAs (Adams et al., 2014), however 
direct links to immune pathways and molecules are less clear and have not yet been 
explored. 
This project investigated the cofactors of TRBP and PACT within this novel context. 
TRBP and PACT have been shown to have direct interaction with PKR, suggesting 
these proteins may also participate in immunity. We focussed on the immune 
checkpoint programmed death ligand 1 (PD-L1) in this project; discussed in section 
1.5.1. 
1.5.1 PD-L1 
PD-L1 is a cluster of differentiation (CD) molecule, also known as CD274 (Kataoka, 
2016). In healthy individuals, PD-L1 is expressed on antigen presenting cells to 
prevent self-activation and targeting of the immune system. PD-L1 binds to induced 
PD-1 receptors on activated T cells to prevent an inflammatory and proliferative 
response (Kier et al., 2008). 
This pathway is also hijacked by cancerous cells to evade the immune response (see 
figure 5). By blocking this interaction with anti-PD-L1 molecules, the immune system 
is able to activate and kill cancerous cells (Powles et al., 2014; Kier et al., 2008). 
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It is known that structural variation to the 3’ UTR of PD-L1 improves the competency 
of a cell to escape the immune response (Kataoka et al., 2016). It is also known that 
PD-L1 expression is regulated post-transcriptionally by miRNAs. MiRNAs frequently 
target the 3’UTR of mRNAs, hence truncation or mutations in this region prevent the 
binding of miRs and consequently reduces post-transcriptional regulation.  
MiR-155 has been identified as a regulator of PD-L1, capable of directly bind the 3’UTR 
(Yee et al., 2017). Within this project, we assess expression of miR-155 upon depletion 
of DICER co-factors. As a canonical microRNA, successful disruption to microRNA 
biogenesis may result in dysregulation of miR-155. This in turn would reduce 
regulation of PD-L1 and we may see an increase in its expression. It should be 
acknowledged that more than 50 further miRNAs have been identified as influencers 
in the cell surface expression of PD-L1 across different cell types (Wang et al., 2017), 
and these should not be forgotten during result interpretation. 
Further to this, increases in dsRNA stress has been linked to an upregulation of PD-L1 
(Sheng et al., 2018). Depletion of cofactors of the miRNA biogenesis pathway may lead 
to a build-up of dsRNA through reduction of processing efficiency. Increased dsRNA 
stress or upregulation of PACT upon TRBP knockdown may also directly activate 
PKR, leading to an inflammatory response and stimulation of PD-L1. 
Figure 5: Suppression of T-cell activation during PD-1, PD-L1 interactions. 
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Both PKR and PD-L1 exhibit responses to stimulation by IFN-γ. IFN-γ is a cytokine 
predominantly secreted by activated T cells, so it makes sense that PD-L1 is 
upregulated upon IFN-γ stimulation (Yee et al., 2017) – in order to prevent T-cell 
mediated death. PKR is similarly activated upon IFN-γ stimulation (Sharma et al., 
2011), subsequently leading to phosphorylation of EIF2α. PKR can also mediate effects 
induced by IFN-γ stimulation such as regulation and differentiation of hematopoietic 
cells (Sharma et al., 2011) and also initiate further transcription factors such as NF-ĸB 
(Zamanian-Daryoush et al., 2007). 
Summarised in figure 6, we know that PKR can interact with components of miRNA 
biogenesis, the inflammatory response through IFN-γ signalling and influence nuclear 
transcription factors. IFN-γ and miRNAs can also influence PD-L1 expression, we 
propose that PKR could potentially act as a mediating molecule between these 
different pathways. It would be interesting to determine if PKR also has a direct 
relationship with PD-L1.  
Figure 6: Visualisation of PKR interactions with miRNA biogenesis, IFN-γ and PD-L1. 
 
1.6 Rationale for use of different cell lines  
Three different cell lines were used throughout this project: HeLa, RCC4 and MDA-
MB-231. HeLa cells originate from a cancerous cervical tumour and were the first 
immortalised human cell line, initially isolated in the 1950s. HeLa cells are used by 
researchers around the world and have been the basis for many miRNA analyses, 
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including the study by Kim et al. (2016). Therefore, we decided to utilise HeLa cells in 
order to reflect these previous studies.  
However, we decided to expand upon this and include a further two cell lines. Due to 
the age of HeLa cells, these have accrued many mutations and hence may no longer 
constitute a reliable cell model. Further to this, we decided to explore different 
tissues, using cell lines from breast cancers (MDA-MB-231) and renal cell carcinoma 
(RCC4). These cell lines were readily available to us and allowed more reliable 
exploration into the roles of TRBP and PACT in ‘general’ miRNA biogenesis and 
immunity, by reducing tissue-type bias.  
RCC4 and MDA-MB-231 cell lines were also chosen due to their expression of PD-L1 
protein. All three chosen cell lines are readily transfectable, hence were ideal options 
for performing RNAi and CRISPR-CAS9 experiments. 
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1.7 Project aims and hypothesis 
The aims of this project were to investigate transient knockdown versus stable 
knockout of TRBP and PACT across three cancer cell lines with a focus on their roles 
in miRNA biogenesis and immunity. We aimed to investigate discrepancies between 
in vitro and in vivo results to date and explore links between the seemingly separate 
pathways of miRNA biogenesis and cellular immunity. 
Individual aims were as follows: 
I. Use RNA interference (RNAi) to transiently knock down TRBP and/or PACT 
II. Assess selected miRNAs to investigate effects on miRNA biogenesis 
III. Evaluate effects on PD-L1, as a means for assessing a novel role of TRBP, PACT 
and microRNA in immunity 
IV. Utilise and design CRISPR / Cas9 genome editing approaches to produce 
TRBP and PACT knockout cell lines 
It was hypothesised that depletion of TRBP alone or in combination with PACT 
would disrupt the biogenesis of microRNAs. We also hypothesised that depletion of 
TRBP and PACT could affect PD-L1 expression through miRNA dysregulation and/or 
PKR mediated mechanisms. 
It was further predicted that stable knockout of TRBP protein would not exhibit a 
reduced DICER processing efficiency, with the suggestion that cancer cells have time 
to compensate for loss of function over time.  
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2. Materials and Methods 
2.1 Mammalian Cell Culture 
HeLa, RCC4 and MDA-MB-231 (MDA231) cells were cultured in Dulbecco’s modified 
Eagle’s Medium (DMEM) (Gibco, Life Technologies), supplemented with 10% foetal 
calf serum (FCS) (Hyclone), 1% 200 mM L-glutamine (Gibco, Life Technologies), and 
1% penicillin/streptomycin (Gibco, Life Technologies). Cells were washed with 1x PBS 
(Gibco, Life Technologies) detached with 0.05% Trypsin-EDTA (1x, Gibco) once 70-
80% confluent, split 1 in 10 and maintained at 37°C in a humidified atmosphere of 5% 
CO2. 
For cryogenic storage, ~1 million cells were gently resuspended in 1 mL freeze media 
(see appendix 6.1) and incubated at -80°C for 48 hours. Cells were then transferred to 
liquid nitrogen for permanent storage. 
For cell thaws, cells were collected from liquid nitrogen and thawed for 1-2 min at 
37°C. Cells were then transferred slowly into pre-warmed DMEM (37°C) and spun at 
259 g to remove residual freeze media. Cells were then resuspended and plated in 
DMEM. 
2.2 RNA Interference (RNAi) 
16 hours prior to transfection, cells were seeded at a density of 50,000 cells per mL per 
well in 6 well plates in antibiotic-free DMEM. Short interfering RNA (siRNA) 
targeting TRBP, PACT or DICER (On-TargetPlus Smartpools, GE Dharmacon) were 
transfected at a final concentration of 50 nM using TransIT-siQuest transfection 
reagent (Mirus Bio), alongside a non-targeting control (NTC) (50 nM, GE 
Dharmacon), in Opti-MEM reduced serum medium (Gibco, Life Technologies). 5-6 
hours later, 1 mL complete DMEM was added to each well and incubated for 16 hours. 
Cells were washed with 1 mL PBS and media replaced with fresh DMEM; samples 
were harvested 48 hours later. 
2.3 RNA Isolation 
Samples were collected with 700 µL QIAzol lysis reagent (Qiagen) directly from 6 well 
culture plates and frozen in -80°C until RNA extraction. 
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Total RNA was isolated using the miRNeasy Kit (Qiagen) according to manufacturer’s 
instructions and eluted in 30 µL nuclease free water. RNA concentration and purity 
was determined using a Nanodrop 2000c UV/vis spectrophotometer (Thermo Fisher 
Scientific). 
2.4 RT-qPCR 
2.4.1 Reverse transcription / cDNA synthesis 
Isolated RNA was reverse transcribed to cDNA with random hexamers or oligoDT 
primers in a c1000 Touch Thermal Cycler (BIO-RAD).  
Random Hexamers: ≥200 ng of RNA sample was added to 1 µL random hexamers 
(50 ng/µL, Promega or Applied Biosystems), 1 µL dNTP mix (10 mM, Thermo 
Scientific) and made up to 10 µL volume with nuclease-free H2O. Samples were pulsed 
in a centrifuge then incubated at 65°C for 5 min, cooled to 4°C for 1 min and kept on 
ice. 4 µL first strand buffer (Invitrogen), 2 μL 0.1M DTT (Invitrogen), 0.5 μL 
RNaseOUT (40 U/µL, Invitrogen), 0.5 μL superscript III (200 U/µL, Invitrogen) and 3 
μL nuclease-free H2O were added to each sample and pulsed in a centrifuge. Samples 
were placed back into the thermal cycler and incubated for 10 min at 25°C, 50 min at 
50°C then 5 min at 85°C to terminate the reaction. Samples were chilled and kept on 
ice before proceeding with qPCR analysis, or stored in -20°C. 
OligoDT primers: ≥200 ng of RNA sample was added to 1 µL anchored oligoDT 
primers (70 µM, Sigma), 1 µL dNTP mix and made up to 12 µL volume with DEPC H2O 
(Ambien). Samples were spun briefly, incubated at 70°C for 6 min then cooled to 4°C 
for 2 min. 4 µL 5x first-strand buffer (Invitrogen), 2 µL DTT (0.1 M, Invitrogen), 1 µL 
RNase OUT (Invitrogen) and 1 µL Superscript II reverse transcriptase (200 U, 
Invitrogen) were added to each sample, spun briefly and incubated at 42°C for 1 hour. 
Samples were heated to 70°C to terminate the reaction, then chilled and kept on ice 
before further analysis, or stored in -20°C. 
2.4.2 Quantitative PCR (qPCR) 
mRNA expression was quantified using the quantitative polymerase chain reaction 
(qPCR), with Sybr Green master max (Applied Biosystems).  
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2.4.2.1 Primer Design 
Primers were designed using BLAST against confirmed mRNA sequences of intended 
targets; primer sequences are shown in table 1. To confirm suitability for use, primers 
were tested on serial diluted cDNA to assess single target amplification (single peak 
melt curve) and amplification efficiency. An amplification efficiency of 100% suggests 
the DNA copy number is doubling with each cycle. To obtain primer efficiency values, 
log copy values are plotted against cycle threshold (CT). The slope of the standard 
curve is then input into a qPCR efficiency calculator such as that provided by 
ThermoFisher Scientific, to obtain an amplification factor value and efficiency; these 
are shown in results (3.1). 
Primers were used at a working concentration of 10 µM. 
Target Forward Primer Reverse Primer 
TRBP GGGAAGACGCCTGTGTACGA GGTGACCCGGAAGGTGAAA 
PACT TTACACGAATACGGCATGAAGAC CAACGGTTACTCTGAAGGTGAAA 
PD-L1 CATCTTATTATGCCTTGGTGTAGCA GGATTACGTCTCCTCCAAATGTG 
DICER CACATGCCTCCTACCACTACAA GCTTGGTTATGAGGTAGTCCAAA 
GAPDH GGAGTCAACGGATTTGGTCGTA GGCAACAATATCCACTTTACCAGAGT 
Table 1: Primers were ordered as custom desalted oligonucleotides from Sigma 
Aldrich. 
2.4.2.2 qPCR 
1 µL cDNA was added to 10 µL SYBR Green Master Mix (Applied Biosystems), 0.6 µL 
custom forward and reverse primers (10 µM) and 7.8 µL nuclease-free H2O in a 
MicroAmp Fast Optical 96 well reaction plate (Applied Biosystems). Plates were 
sealed with MicroAmp Optical adhesive film (Applied Biosystems), before 
centrifugation at 1200g for 1.5 min.  
Plates were run in StepOnePlus™ Real-Time PCR Systems (Applied Biosystems) for 40 
cycles (95°C - 60°C), with a set cycle threshold of 0.1 ΔRn (ΔRn (Δreaction) refers to 
change in fluorescent signal). Base thresholds were set automatically by StepOnePlus 
Software (V2.3).  
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All experimental samples had experimental controls, therefore relative gene 
expression was calculated using the comparative CT method (ΔΔCT). GAPDH was 
used as a housekeeping gene. 
 
𝛥𝐶𝑇 = (𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑇𝑒𝑠𝑡 𝐶𝑇 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐻𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔 𝐶𝑇) 
𝛥𝛥𝐶𝑇 =  (𝑇𝑒𝑠𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 𝛥𝐶𝑇  −   𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝛥𝐶𝑇) 
𝑚𝑅𝑁𝐴 𝑓𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 = 2^(−𝛥𝛥𝐶𝑇) 
 
2.5 MicroRNA RT-qPCR 
2.5.1 MicroRNA reverse transcription / cDNA synthesis 
1-5ng of total isolated RNA was reverse transcribed to miRNA cDNA using TaqMan® 
miRNA reverse transcription Kit (Applied Biosystems) according to manufacturer 
instructions. cDNA was made in separate PCR strips for each target. 
2.5.2 MicroRNA qPCR 
miRNA expression was quantified by qPCR using TaqMan Universal Master Mix II 
(Applied Biosystems) and relative gene expression calculated using the ΔΔCT method 
as described in 2.4.2.  
2.6 Western blot 
2.6.1 Sample collection 
Cells were washed with ice cold PBS and lysed with 30-40µL 
radioimmunoprecipitation assay (RIPA) buffer (see appendix 6.1) containing protease 
and phosphatase mixture inhibitors P8340, P5726, and P0044 (1:100) (Sigma). Cells 
were scraped from the plate with a cell scraper and kept on ice before centrifugation 
at 10,000 g for 15 min at 4°C. Pelleted cell debris was removed, and protein was stored 
at -20°C. 
2.6.2 Protein quantification 
Protein samples were quantified using a Pierce bicinchoninic acid (BCA) protein 
assay kit (Thermo Scientific) against serially diluted bovine serum albumin standards 
(2000 µg – 31.25 µg). Samples were diluted 1 in 6 with PBS and 5 µL added to 95 µL 
31 
 
BCA reagent mixture in a 96 well plate. These were incubated at 37°C for 30 min and 
absorbance was read in a VERSAmax microplate reader (Molecular Devices) at a 
wavelength of 562. 
2.6.3 Gel, transfer and antibody incubations 
Samples were made up to ≤10µg protein in a total volume of 20 µL with ddH2O and 5 
µL 4x loading buffer (see appendix 6.1), prior to denaturation at 95°C for 10 min. 
Samples were kept on ice before loading. 
17 µL of sample was loaded into a stacking gel and resolved on SDSPAGE gels (8-10%, 
see appendix 6.1) in SDS-Page running buffer (National Diagnostics) for 1.5 hrs, 120 V 
using a Bio-Rad PowerPac HC and mini-PROTEAN tetra system.  
Protein was transferred onto PVDF membranes (0.45 µm, Immobilon) with transfer 
buffer (National Diagnostics) supplemented with 10% methanol, using a Trans-Blot 
SD Semi-Dry Transfer Cell (Bio-Rad) at 25 V, 0.2 amp for 45 min. Membranes were 
activated in methanol for 1 min prior to transfer and held in transfer buffer. 
Post-transfer, membranes were blocked in 2% Bovine Serum Albumin (BSA) (Fisher 
Scientific) in 0.1% TBST (see appendix 6.1) for 1 hour on a rocking platform. Primary 
antibodies, shown in table 2, were probed overnight at 4°C in a 50 mL falcon tube on 
a roller mixer. Loading controls indicated by * were incubated for 1hr at room 
temperature (RT). 
Target Antibody Suspension 
TRBP ProteinTech, 15753-1-AP 1:2000. 4% (w/v) BSA in 0.1% TBST 
PACT Abcam, ab31967 1:1000. 4% (w/v) BSA in 0.1% TBST 
DICER Cell Signaling Technology, 
D38E7 
1:1000, 5% (w/v) Milk in 0.1% TBST 
PD-L1 Cell Signaling Technology, E1L3N 1:1000, 5% (w/v) Milk in 0.1% TBST 
PSTAT1 Cell Signaling Technology, D4A7 1:1000, 5% (w/v) BSA in 0.1% TBST 
STAT1 Cell Signaling Technology, #9172 1:1000, 5% (w/v) BSA in 0.1% TBST 
GAPDH* Abcam, [6C5] 1:5000, 5% (w/v) Milk in 0.1% TBST 
β-Actin* Abcam, [AC-15] ab6276 1:5000, 5% (w/v) Milk in 0.1% TBST 
Table 2: Antibodies utilised for western blot 
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Membranes were washed 3 x 5 min in 0.1% TBST with constant movement. 
Horseradish peroxidase (HRP) conjugated anti-rabbit and anti-mouse secondary 
antibodies (Dako) were then incubated for 1 hour at room temperature. Membranes 
were washed a further 3 times before visualization with Amersham ECL Western 
Blotting Detection Reagents (GE Healthcare). Luminol detection was either by 
Amersham Hyperfilm (GE Healthcare) using a compact X4 film processor (Xograph), 
or by ChemiDOC (BIO-RAD). 
Membranes were probed for multiple primary antibodies and were consequently 
stripped between protein targets of similar sizes. Membranes were stripped for ~15 
mins in Restore Western Blot Stripping Buffer (Thermo Fisher) at RT on a rocking 
platform, then blocked and probed as before. 
2.6.4 Western blot quantification 
Western blot images were saved as high quality TIFs and quantified using ImageJ 
software. All probed targets were normalised to either GAPDH or β-Actin and test 
samples are shown relative to experimental controls. 
2.7 CRISPR / CAS9 Genome Editing 
2.7.1 gRNA 
Off-the-shelf crRNA was bought from GE Dharmacon and validated using BLAST 
software. crRNA (or CRISPR RNA) is the sequence specific region of guide RNA that 
directs Cas9 to the complementary region of the genome.  
crRNA sequences are shown in table 3. Both sequences for each target were pooled to 
increase likelihood of producing a knockout cell line. crRNA1 for TARBP2 and PRKRA 
target coding strands, where crRNA 2 targets lag strands, though both would create 
double strand breaks. See figure 7 for depiction of TARBP2 crRNA targets. crRNA for 
PRKRA targets domain 2 (sequence 1), and a non-protein-coding region of the gene. 
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Target crRNA 1 crRNA 2 
TARBP2 TCCTCATACCCTGGTCTTAT 
(CM-017430-02-0002) 
TTAAAGTGGAAGGCCCAGTG 
(CM-017430-01-0002) 
PRKRA AACGTCCGATCTCAGTAAAT 
(CM-006426-02-0002) 
TAAACCGTACGTTTCGTGTG 
(CM-006426-01-0002) 
Table 3: crRNA sequences used in liposomal CRISPR Cas9 protocol 
 
 
 
 
Figure 7: TRBP crRNA target sites (Domain 1) 
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2.7.2 Liposomal Delivery 
See figure 8: HeLa, RCC4 or MDA-MB-231 cell lines were transfected with a Cas9 
expressing plasmid (Edit-R Cas9 Expression Plasmids, hCMV promoter, puromycin 
resistant, GE Healthcare), crRNA as described in section 2.7.1 and trans-activating 
CRISPR RNA (tracrRNA) (Edit-R, GE Healthcare) according to protocol (Edit-R Cas9 
Expression Plasmids and Synthetic RNAs Technical Manual). Two transfection 
reagents were trialled: DharmFECT Duo (GE Healthcare) and jetPRIME (Polyplus 
Transfection). 
Figure 8: Example workflow – liposomal delivery of gene editing components (Dharmacon GE 
Healthcare) 
2.7.3 Puromycin Kill Curve(s) 
≥ 48 hours post transfection, cells were selected with puromycin (1000x (100 mg/ml)). 
Due to the survival of control HeLa cells, kill curves were determined to ensure the 
correct puromycin dosage. Alamar blue (Thermo Scientific) was used to estimate cell 
survival. Cells were plated in serial dilutions and exposed to 0, 2.5, 5, 7.5, 10 and 15 
µg/mL of puromycin. 24-hours after the addition of puromycin, alamar blue reagent 
was added to wells and incubated for four hours, 37°C, away from direct light sources. 
Plates were then read in a VERSAmax microplate reader (Molecular Devices) at a 
wavelength of 570 and normalized to 600 nm. Reduction in absorbance indicates 
increased cell viability, based on reduction of Resazurin (Thermo Scientific – alamar 
blue). Results can be seen in section 3.6. 
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2.7.4 Transfection Efficiency  
Plasmid transfection was confirmed using a fluorescent mKate 2 variant Cas9 
expressing plasmid (GE Healthcare) (Excitation / Emission = 58823 / 633 nm). Cells 
were transfected as described in 2.7.2, however no gRNA was inserted into the 
transfection medium. DharmaFECT Duo and jetPRIME transfection reagents were 
tested in order to determine the best reagent moving forwards.  
Cells were analysed 24 hours post-transfection in order to minimalise any loss of 
fluorescent signal. Cells were detached with 150µL Accutase Solution (Biolegend) for 
10 min, before the addition of 400 µL cold DMEM and kept on ice. Samples were then 
spun at 4°C, 285 g for 5 min. Supernatant was aspirated from the pellet, then the 
pellet was washed in 900 µL FACS buffer (see appendix 6.1). Cells were resuspended 
in 400 µL of FACS buffer and kept on ice before analysis. 
 
Samples were run through a LSRFortessa X-20 (BD) Flow Cytometer and analysed by 
FlowJo software. Example sequential gating is shown in figure 9; fluorescence was 
measured using a YG610_20 filter. 
2.7.5 Cell Sorting 
Cells were transfected as described in 2.7.2, using DharmaFECT Duo reagent. 24 
hours post transfection, cells were collected with 200µL accutase and resuspended in 
300 µL DMEM. Samples were then run through a MoFlo Astrios EQ Cell Sorter, where 
cells with a higher fluorescence intensity were collected for further culturing. Cells 
were gated as described in 2.7.4, however due to differences in equipment, 
fluorescence was detected with a 561-614/20 filter. 
Cells were collected in ~2 mL of DMEM, centrifuged for 15 min, 259 g, room 
temperature, then resuspended in the same media before plating into a 24-well plate. 
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2.7.6 Lentiviral Production and Delivery 
2.7.6.1 Plasmid transformation and isolation 
Plasmid Source 
lentiCRISPR v2 Addgene (Plasmid #52961) 
VSV.G envelope plasmid Addgene (Plasmid #14888) 
Δ8.14 packaging plasmid Addgene (Plasmid #79047) 
pUC18 control plasmid Addgene (Plasmid #50004) 
Table 4: Plamids used throughout lentiviral CRISPR Cas9 protocol 
Plasmids described in table 4 were transformed into XL1-blue competent bacterial 
cells (Agilent) using a heat shock method. 50 – 500 ng of plasmid was added to 30 µL 
XL1 cells and incubated on ice for 30 min. Samples were transferred to a 42°C water 
bath for 42 seconds then incubated on ice for 2 min. 700 µL of SOC media (see 
appendix 6.1) was added to each tube, and samples were incubated at 37°C for 1 hour 
with movement. Transformed bacteria were spread onto ampicillin resistant agar 
plates (see appendix 6.1) and incubated overnight at 37°C. Positive and negative 
controls were used at this point to ensure ampicillin selection results. 
Single colonies were selected the next day, inoculated into 10mL LB broth and 
incubated at 37°C overnight with shaking (180-200 RPM). Samples were then stored 
in 4°C over the weekend before being grown in 50 mL LB broth for 6 hours prior to 
isolation (37°C with shaking). 
Plasmids were re-isolated using the QIAGEN Plasmid Midi Kit according to 
manufacturer instructions and stored at -20°C. 
2.7.6.2 Lentivirus assembly and harvest 
Lentiviral particles were produced using HEK-293T cells as the packaging cell line; 
confluent 10cm2 cell dishes were split 1:7 one day before transfection and spread 
evenly onto fresh culture plates. Three plasmids as described in 2.2.6.1 were 
transfected to each plate; 5 µg of DNA was transfected in total (2 µg lentiCRISPR, 1.5 
µg VSV.G and 1.5 µg Δ8.14) and was made up to 50 mL with opti-MEM. The plasmid 
mixture was added to 15 µL Fugene transfection reagent (3 µL per µg DNA, Promega) 
in 35 µL opti-MEM, thus 100 µL of transfection mix was added to each plate 
containing 8 mL fresh opti-MEM.  
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1 plate of HEK-293T cells was transfected with GFP plasmid, VSV.G and Δ8.14 to act as 
a control and confirm that uptake of the plasmid into the packaging cell line was 
successful. 
5 hours post-transfection, the transfection medium was removed and replaced with 
10mL DMEM (with 10% FCS, 1% pen-strep). Viral particles were harvested and filtered 
(0.45 µM) 48 hours later, and stored in -80°C. 
2.7.6.3 Infection 
RCC4 cells were seeded at a density of 75,000 cells/well in a 6-well culture plate in 
DMEM supplemented with 10% FCS. 16 hours later, virus collected in 2.7.6.2 was 
thawed on ice before being warmed to 37°C for 2-3 min. Media was aspirated from 
wells and replaced with 1 mL of CRISPR or GFP lentivirus. Successful lentiviral 
infection was confirmed by fluorescent microscopy of GFP infected cells. CRISPR 
infected cells were selected with puromycin 48 hours later, though due to expected 
cell death, half of the infected cells were kept for western blot analysis. No Cas9 was 
detected (results not shown).  
2.8 Co-Immunoprecipitation Assay 
Two confluent 10cm2 plates of HeLa, RCC4 and MDA-MB-231 cells were washed with 
ice-cold PBS and lysed with 500 µL 1x Cell Lysis Buffer (Cell Signalling Technologies, 
#9803) supplemented with 1 mM PMSF protease inhibitor mix (Cell Signalling 
Technologies, #8553). Cells were scraped and both plates of each cell line pooled 
together before filtration with a 25 g needle. Samples were spun at 14,000 g for 10 min 
at 4°C, half of each supernatant was frozen in -80°C whilst the other half was taken 
forward to pre-clearing. 
Lysates were pre-cleared for non-specific binding to beads with 2 µg normal rabbit 
IgG (Cell Signalling Technology, #2729) incubated at 4°C for 1-4 hours, 25 RPM. IgG 
was pulled down with 20 µL of pre-washed bead slurry (Protein A Agarose Beads, Cell 
Signalling Technologies, #9863), incubated at RT for 30 min, 25 RPM. Beads were 
pelleted at 8000 g for 1 min at RT and supernatant was carried forward for TRBP co-
immunoprecipitation.  
Supernatant for each cell line was split into 3 separate tubes (200 µL per tube), one 
aliquot was frozen in -80°C and is henceforth referred to as ‘input’. 3 µg of TRBP or 
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IgG primary antibody was added to the remaining cell lysates and incubated with 
gentle rotation (25 RPM) overnight at 4°C.  
The next day, cell lysates were added to 20 µL bead slurry and incubated at 4°C, 25 
RPM for 2.5 hours. Beads were then pelleted at 8000 g for 1 min and washed 5x with 
1X Cell Lysis Buffer before resuspension in 20 µL sample buffer (see appendix 6.1). 
Sample buffer was also added to 5% input (10 µL) and all samples were denatured for 
5 min at 95°C. Analysis was completed by western blot (10% gel), with the addition of 
a confirmation antibody (Cell Signalling Technologies, #3678, 1:2000 in 5% milk, 0.1% 
TBST) used between primary antibody incubations and secondary HRP antibody 
incubation. This was incubated at RT for 1 hour.  
 
2.9 Statistics 
Statistical analysis was completed using GraphPad Prism 6 software. Specific 
statistical analysis is indicated upon each graph legend. 
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3. Results 
3.1 DICER co-factors TRBP and PACT do not regulate one another 
Previous findings in literature suggest that TRBP and PACT do not regulate or 
compensate for one another (Kim et al., 2014). However, these results originate from 
stable loss of function, whereas within this project, we assess transient protein 
knockdown. Therefore, we explore the possibility that upon knockdown, cells do not 
have time to compensate for loss of function, and therefore we may see a regulatory 
or compensatory effect upon TRBP or PACT knockdown. 
Messenger RNA and protein levels were assessed 48 hours post transfection of siRNA 
against TRBP and/or PACT. Primers used in qPCR assays were confirmed to amplify 
only the intended target through melt curve analysis, with efficiency assessed via 
standard curve as shown in figure 10. We confirm downregulation of target mRNA in 
figure 11, within HeLa (figure 11a), RCC4 (11b) and MDA-MB-231 (11c) cell lines, and 
observe no consistent regulatory effects. We identified a significant upregulation of 
PACT upon knockdown of TRBP in MDA231 cells, though this is less than a 0.5-fold 
change and not observed across any other cell line. 
 
Figure 10: Geometric efficiency assessment of custom primer amplification 
 
40 
 
TRBP has been observed to ensure efficient DICER processing in vitro (Fareh et al., 
2016). Therefore, upon depletion of TRBP (and/or PACT), if TRBP (and/or PACT) has 
a measurable contribution to DICER processing, you could expect to see either loss of 
function or some compensation. One possible mechanism might be an upregulation 
in DICER levels to compensate for reduced processing activity of the enzyme in the 
absence of its co-factor TRBP. We observe this trend in HeLa cells, but not in the 
renal or breast cancer lines and thus are unable to conclude if this is a compensatory 
effect.  
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Figure 11: mRNA levels were measured by RT-qPCR 48 hours after transfection with siRNA against TRBP, PACT or 
DICER in HeLa (a), RCC4 (b) and MDA-MB-231 (c) cell lines. Results were normalised to non-targeting controls and 
assessed by two-way analysis of variance with Dunnett’s multiple comparisons test. **, p = <0.01, ***, p = 0.001, ****, p = 
<0.0001. (d) DICER mRNA levels across HeLa, RCC4 and MDA231 cell lines also 48 hours post-transfection. 
a ) b )
c ) D IC E R
m
R
N
A
 f
o
ld
 c
h
a
n
g
e
H
e
L
a
R
C
C
4
 
M
D
A
-M
B
-2
3
1
0
1
2
3
4
**
*
* *
d )
C o n tro l
s iT R B P
s iP A C T
s iT R B P  &  s iP A C T
s iD iC E R
 
Upon transfection of siRNA against DICER, we confirmed significant reduction of 
DICER mRNA (11,d), and observed limited trends of regulation between DICER and 
its co-factors across the three cancer lines: upon dual knockdown of TRBP and PACT 
an increase in DICER mRNA is seen for HeLa, RCC4 and MDA-MB-231 cells, though 
this is only significant in HeLa cells.  
Figure 12 demonstrates successful reduction of TRBP and PACT protein in 
appropriate RNAi samples. Multiple bands are present for TRBP probes, indicating 
various states of protein phosphorylation (phosphositeplus.org). In RCC4 and MDA-
MB-231 lines, a mild upregulation of TRBP is observed upon knockdown of PACT. 
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However, as evident from the representative western blots (figure 12a, figure 18) and 
biological replicates indicated by quantification (12c, 12d), this was not a unanimous 
trend and could merely be natural variance between samples, Alternately, this could 
be a knock-on effect from miRNA dysregulation, as this trend was not observed in 
mRNA levels (figure 11). 
 
3.2 Individual knockdown of TRBP or PACT does not affect microRNA 
abundance 
Four microRNAs were chosen for analysis upon knockdown of TRBP and PACT. 
MicroRNA (miR) 21 was identified as a ubiquitous miRNA in cancer cells, whereas 
miR-16 is deleted in some cancers. (Buscagalia and Li, 2011, Calin et al., 2002). Here we 
show that miR’s 16 and 21 were consistently more abundant than the snRNA U6 in all 
cell lines utilised in this project (see figure 16), suggesting these are ubiquitously 
expressed in HeLa, RCC4 and MDA-MB-231 cell lines. These have been utilised as 
markers of disruption to canonical miRNA biogenesis.  
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Figure 13: Change in CT values of selected microRNAs against U6, used as a housekeeping gene (average 
housekeeping CT – average test CT). miR-16 and miR-21 are ubiquitously expressed in HeLa, RCC4 and 
MDA-MB-231 cell lines, regularly reaching cycle threshold before the highly conserved small nuclear RNA 
(snRNA) U6.  
 
MiR-155 was investigated owing to its roles as a marker of inflammation (reviewed by 
Tili et al., 2009) and regulator of the checkpoint protein PD-L1 (Yee et al., 2017), 
where it has been identified to directly target the 3’ UTR of PD-L1. MiR-221 was 
chosen because it is overexpressed and promotes tumorigenesis in triple negative 
breast cancer lines, such as the MDA231 line (Nassirpour et al., 2013). This is in 
comparison to ‘normal’ breast tissue; within this study we found miR-221 to be lowly 
expressed in MDA231 cells, though we did not have a healthy control for contrast. 
Independent depletion of TRBP or PACT had no effect on the abundance of 
ubiquitous microRNAs (figure 14). Curiously, siDICER samples also presented with no 
reduction of canonical miRNAs.  
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Figure 14: MicroRNAs 16 (a, e, i), 21 (b, f, j), 155, (c, g, k) and 221 (d, h, l) were assessed by RT-qPCR in HeLa (a ,b, c, d), 
RCC4 (e, f, g, h) and MDA-MB-231 (I, j, k, l) cell lines after RNAi treatment against TRBP, PACT or DICER. One-way analysis of 
variance was conducted with Dunnett’s multiple comparison test, with no significant results. N = 3 independent samples 
a) b) c) d) 
e) f) g) h) 
i) j) k) l) 
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3.3 Depletion of both TRBP and PACT leads to downregulation of 
ubiquitous microRNAs 
TRBP and PACT may function synergistically: when both DICER co-factors were 
depleted, a common trend emerged. Both selected ubiquitous miRNAs were 
downregulated across all three cell lines, with the most significant and exaggerated 
reduction observed in MDA-MB-231 cells (figure 15). This may suggest that although 
TRBP and PACT do not regulate one another on a protein or mRNA level, they may 
compensate for one another in certain functions.  
It is already established that TRBP and PACT interact physically in vitro (Singh et al., 
2011) and can form homodimers and heterodimers with each other (Heyam et al., 
2017, Laraki et al., 2008). We predicted that TRBP and PACT also interact within a 
natural cellular environment, and that levels of interaction may vary between these 
cell types. Heterodimer interactions could indicate binding for protein stability, 
functional regulation or joint functionality. This is explored in section 3.5 and 
discussed in section 4. 
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Figure 15: miR-16 and miR-21 were assessed by RT-qPCR in HeLa, RCC4 and MDA-MB-231 cells 48 hours post-
transfection with siRNA against TRBP and PACT. Statistical analysis by unpaired Student’s t test, *, p <0.05, ***, p = 
0.0005, ****, p <0.0001. n = 3 independent samples 
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MiR-155 and miR-221 did not exhibit consistent downregulation upon depletion of 
TRBP and/or PACT (figure 16). With one exception (miR-155, RCC4), these 
microRNAs are lowly expressed in the tested cancerous cell lines, as shown by figure 
13. Disruption to biogenesis may be less evident in lowly expressed miRs due to their 
longevity. In general, microRNAs are stable transcripts, with longevity lasting from a 
few hours to several weeks (reviewed by Zhang et al., 2013). Lowly expressed miRs are 
less likely to be processed, or exhibit lower levels of processing from pre-miRNA to 
mature complexes, during the 48-hour experimentation period, in comparison to 
highly expressed miRs. Thus, disruption to their biogenesis may be less evident. 
In fact, low expression levels may reduce the reliability of these results due to 
sensitivity of software during the latter qPCR cycles. In contrast to HeLa and MDA231 
cells, miR-155 is highly expressed in RCC4 cell lines, and again we see a similar trend 
of downregulation as noted for miR-16 and miR-21. This further supports the idea that 
TRBP and PACT can compensate for one another in microRNA processing efficiency. 
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Figure 16: miR-155 and miR-221 were assessed via RT-qPCR 48 hours post-transfection with siRNA against TRBP and 
PACT. Statistical analysis by unpaired Student’s t test, *, p = 0.0111, **, p = 0.0061 n = 3 independent samples 
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3.4 PACT depletion leads to upregulation of PD-L1 in breast cancer cells 
In order to explore links between microRNA biogenesis and immunity, PD-L1 
abundance was also measured after knockdown of the DICER co-factors in HeLa, 
RCC4 and MDA231 cell lines. Change in PD-L1 mRNA was measured by RT-qPCR 
(figure 17) and PD-L1 protein by western blot (figures 18 and 19).  
No significant changes in steady-state levels of PD-L1 mRNA was identified, though a 
trend of upregulation can be seen in HeLa samples upon treatment with siTRBP and 
siPACT (figure 18). However, PD-L1 mRNA is very lowly expressed in HeLa cells, and 
even with this upregulation, no protein can be detected (figure 18a) due to the very 
low levels of mRNA present (shown by ΔCT values, figure 17b). 
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Figure 17: mRNA levels were measured by RT-qPCR 48 hours post-transfection with interfering RNA. (a,c,e) mRNA 
expression fold change, analysed by the comparative CT method as described in 2.5.2. (b,d,f) CT values relative to GAPDH. 
One-way analysis of variance with Dunnett’s multiple comparisons test result in no significant findings. 
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Initial western blot results identified a 2-3-fold upregulation of PD-L1 upon 
knockdown of PACT but not TRBP in MDA-MB-231 cells (figure 18). Though 
statistical testing identifies a more significant upregulation of PD-L1 upon knockdown 
of both TRBP and PACT, these results overlap with biological replicate experiments of 
sole PACT depletion, and thus the results seen are likely due to reduction of PACT 
alone. Multiple bands are present for PD-L1 and indicate post-translational 
modifications such as glycosylation of PD-L1 protein (Li et al., 2016). 
It was proposed that stimulation with interferon gamma (IFN-γ) could enhance or 
exaggerate this result, by upregulating PD-L1. STAT1 is phosphorylated to phospho-
STAT1 (PSTAT1) upstream of PD-L1 during stimulation with IFN-γ (Garcia-Diaz et al., 
2017). These were both measured by western blot after TRBP and PACT knockdown 
to identify whether changes in PD-L1 expression were due to upstream effects upon 
the IFN pathway. 
As shown in figure 19, without stimulation we observe a mild upregulation of STAT1 
in RCC4 cells upon dual knockdown of TRBP and PACT. This trend is also observed 
in MDA-MB-231 cells, however this is not statistically significant. Across both cell 
lines, this upregulation is mild and variable, ranging from 1.4 (RCC4, 18b) to 3 
(MDA231, not on representative blot). Independent knockdown of PACT results in 
upregulation of STAT1 in MDA231 cells. This is discussed later in section 4. 
Upon stimulation with IFN-γ, we observe the expected upregulation of STAT1, 
PSTAT1 and PD-L1, shown in figure 18. No reproducible effects upon PD-L1 were 
observed in these cell lines when treated with siRNAs and IFN-γ; interferon 
stimulation eclipses any previously observed results. Therefore, we can propose that 
neither TRBP or PACT are directly involved in the cellular pathways from IFN-γ 
stimulation through to PD-L1 upregulation.  
Of note, we again observe cell line variability between the cancer lines utilised. 
Intriguingly, it is the MDA-MB-231 cell line that has exhibited the most pronounced 
effects of TRBP or PACT depletion related to both microRNA abundance and PD-L1 
upregulation. This is explored further in section 3.5. 
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Figure 19: Western blot quantification of Non-stimulated and IFN-γ treated HeLa (a,b), RCC4 (c,d) and MDA-MB-231 (e,f) 
cell lines. Samples are normalised against a non-targeting control and are relative to β-Actin. Two-way analysis of variance 
was calculated using Dunnett’s multiple comparisons test. *, p = <0.1, **, p = <0.01. 
a ) b )
c ) d )
e ) f )
 
3.5 TRBP and PACT interact endogenously 
Cell line specific variation was observed upon knockdown of TRBP and PACT on both 
microRNA and PD-L1 expression, with the MDA231 breast cancer line exhibiting more 
pronounced effects than the HeLa or RCC4 lines. Reduction of ubiquitous miRNAs 
was only apparent upon dual knockdown of both DICER co-factors suggesting that 
these two proteins may compensate functionally. 
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TRBP and PACT have already been shown to interact in vitro (Singh et al., 2011, Kok et 
al., 2007). We hypothesised that they also interact endogenously in these cells and 
that this interaction may vary dependant on cell type. A higher level of interaction 
would be expected to reduce the abundance of protein available for other cellular 
pathways such as microRNA biogenesis, hence depletion of said protein may then 
have more pronounced effects on these pathways. In accordance with these results 
and hypothesis, we expected a higher interaction of TRBP and PACT in the MDA231 
cell line and the lowest interaction in the RCC4 cell line.  
To test this hypothesis, an endogenous co-immunoprecipitation (co-IP) assay was 
conducted. TRBP was immunoprecipitated from each cell line and analysed by 
western blot (figure 20). It is confirmed that TRBP and PACT do interact 
endogenously in human cell lines. 
 
Enrichment of PACT compared to 2.5% of the assay input is evident for all three cell 
lines, meaning that more than 2.5% of cellular PACT was pulled down. This was 
quantified using ImageJ software for an estimation of protein pulldown and displayed 
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as a percentage of the total input in figure 20. MDA-MB-231 presented with the lowest 
level of PACT pulldown, whilst RCC4 displayed the highest level, contrary to 
predictions. 
No negative control was used for this experiment. In future, a probe should be used 
that is not expected to co-immunoprecipitate with the protein of interest. 
3.6 CRISPR / CAS9 Editing 
This project utilised transient knockdown to assess protein function, however the 
gold standard for assessing endogenous gene and protein function is to produce a 
stable gene knockout cell line for analysis. This is because there will be residual levels 
of protein during transient knockdown and often the abundance of protein required 
for individual cellular functions is unknown.  
To this extent, we utilised gene editing technology to begin the process of producing 
TRBP and PACT knockout cell lines. Another aim of using this technology was to 
enable comparison of transient vs stable depletion of protein within the same project, 
where it would be expected that stable knockout would complement studies already 
present in literature. 
HeLa and RCC4 cells were initially transfected with genome editing components 
described in 2.7 as per protocol. One batch of HeLa cells displayed resistance to 
puromycin (figure 21); these were discontinued, and a fresh stock that were not 
resistant to puromycin were taken from cryogenic storage. A puromycin 
concentration of 2.5µg/mL was sufficient to kill HeLa, RCC4 and MDA-MB-231 cells at 
both high and low cell densities (figure 21).  
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Figure 21: Alamar blue cell-based survival assay of HeLa, RCC4 and MDA-MB-231 cells following exposure to puromycin 
titrations (0 to 15 µg/mL). A baseline absorbency reading is indicated on each kill curve. 
 
Due to complete cell death post-transfection of genome editing components and after 
selection with appropriate concentrations of puromycin, HeLa and RCC4 cells were 
instead transfected with an MKate2 fluorescent Cas9 expressing plasmid, to ensure 
that transfection was taking place successfully. 
A shift in fluorescence was observed between each control and test sample (figure 22), 
suggesting that transfection was successful. These results were quantified, using 
counts of individual cells that presented with an increased level of fluorescence over 
those that fell within the gate of the control samples (figure 23). This in turn was 
compared with cell survival, estimated from sequential gating described in 2.7.4. It 
was observed that Jetprime transfection reagent resulted in a higher transfection 
efficiency than Dharmacon transfection reagents, however Jetprime reagents 
presented with a higher level of cell death.  
15 to 30% transfection efficiency (figure 23) was lower than expected. Transfection 
optimisation should have been conducted with positive controls to obtain the highest 
genomic editing with >70% post-transfection cell viability as recommended 
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(Dharmacon Edit-R CRISPR-Cas9). Low transfection efficiency could be a result of 
improper cell confluency, or plasmid / gRNA to transfection reagent ratio.
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Figure 22: HeLa and RCC4 cells were transfected with a far-red fluorescent mKate2 plasmid expressing Cas9, using DharmaFECT Duo transfection reagent or 
Jetprime transfection reagent. Sequential gating based on FFS and SSC as described in figure 9 (section 2.7.4) was used to determine live, single cell 
populations, where fluorescence was measured with the YG610_20 filter (excitation / emission for mKate2 = 588 / 633 nm). Control samples without plasmid 
were used to set gates to determine shifts in fluorescence.  
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However, due to time restraints, upon successful (but low efficiency) transfection 
with the fluoresenct MKate 2 plasmid, HeLa cells were again transfected and run 
through a MoFlo Astrios EQ Cell Sorter with intent to culture the cells with enhanced 
fluorescence. Owing to differences in filters between the LSRFortessa X-20 (BD) Flow 
Cytometer and MoFlo Astrios EQ Cell Sorter (see section 2.7.4), the enhanced 
fluorescence was not easily detectable, and of the cells isolated for re-culturing (table 
5), none survived. Cells were checked on the LSRFortessa on the same day, showing 
stable protein expression of the fluorescent plasmid (results not collected). 
As a control, cells were transfected using the MDA-MB-231 cell line and harvested for 
western blot analysis before puromycin selection to assess whether any reduction in 
target protein was achieved. CAS9 was also probed. Figure 24 confirms that no 
identifiable reduction in TRBP or PACT was present as compared to the CAS9 control 
lane. No CAS9 protein could be identified in any sample, however it would have been 
ideal to run a positive control to ensure correct exposures of the membranes; though 
the antibody was confirmed to recognise Cas9 by other members of the laboratory. 
 
 
Due to continued cell death after puromycin selection and no confirmation in protein 
reduction upon liposomal transfection, an alternative method of CRISPR editing was 
attempted. It was hypothesised that although transfection of the Puro and MKate2 
plasmids were successful, the promoters on the plasmid were not successfully 
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initiating transcription. Therefore, a lentiCRISPR system was trialled as this would 
incorporate CAS9 into the host genome.  
A GFP plasmid was utilised alongside a lentiCRISPR plasmid in order to confirm 
successful packaging of the virus and successful infection of chosen cell lines. GFP 
was successfully expressed in control samples (results not shown), but no Cas9 was 
detectable upon analysis of edited cells, and no edited cell survived puromycin 
selection. 
The lentiCRISPR V2 (Addgene plasmid #52961) has been fully sequenced and 
documented in literature, firstly by the depositing lab (Sanjana et al., 2014) and more 
recently (Zhang et al., 2019; Yuan et al., 2019). It is likely that no detectable Cas9 in 
this circumstance was due to poor detection of this protein, or unsuccessful plasmid 
transfection / packaging, owing to differing properties such as size (14.8 kb) to the 
control GFP plasmid. 
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4. Discussion 
This project aimed to investigate the role(s) of TRBP and PACT within microRNA 
biogenesis by performing transient knockdown and stable gene knockout 
experiments within human cancer cells. We also aimed to investigate potential 
crosstalk between miRNA machinery and immunity through investigation of the 
immune checkpoint protein PD-L1. 
To fulfil these objectives, we successfully performed RNAi experimentations to 
deplete TRBP and PACT individually and concurrently. We expanded on previous cell 
work by inclusion of three different cancer cell lines, however were unable to provide 
comparisons between transient and stable depletion of proteins due to technical 
difficulties and time constraints. 
4.1 Depletion of TRBP and PACT is required for suppression of miRNA 
expression in cancer cells 
We identified a novel effect on abundance of highly expressed microRNAs after 
depletion of TRBP and PACT in three different cancer cell lines. These included miR-
16 and miR-21 within HeLa, RCC4 and MDA-MB-231 lines, miR-155 within RCC4 lines 
and miR-221 in HeLa cell lines. Only upon depletion of both proteins was disruption 
to mature miRNA abundance observed, a finding not previously identified in cellular 
studies. We present the possibility that TRBP and PACT act synergistically on 
regulating the levels of specific miRNAs, though how conserved this mechanism is at 
the global level is still unknown and requires further study.  
TRBP and PACT are structural homologs: both bind DICER with their third domain, 
both have unstructured linker regions allowing movement between domains, and 
both domains one and two bind RNA (Heyam et al., 2015). These qualities grant both 
proteins the ability the ensure efficient DICER processing in line with the theory 
presented by Fareh et al. (2016), whereupon these dsRBDs bind RNA first and then 
present substrates to DICER in an optimum orientation. This prevents full loading of 
unrecognised substrates onto DICER, increasing processing efficiency. 
Fareh et al. (2016) did not investigate PACT’s ability to alter DICER processing during 
reconstitution experimentation with TRBP. However, Kim et al. (2014) report TRBP, 
PACT and double knockout HeLa cell lines, upon which no change in microRNA 
abundance was observed. This leaves ambiguity: it has been demonstrated that TRBP 
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has the ability to aid DICER’s ability to distinguish pre-miRNAs from other RNAs, 
though the effects of this are not demonstrated in a stable knockout cell line. A 
similar occurrence could be found for PACT, but as yet it is uncertain is PACT has the 
functional capacity for ensuring efficient DICER processing. 
Kim et al. (2014) suggest that TRBP and PACT do not compensate for one another. 
Based on the findings of this project, we propose that TRBP and PACT may 
compensate functionally in the loading of miRNA to/from DICER. It is acknowledged 
that this may not be evident in a genome-edited, stable knockout of TRBP and/or 
PACT. 
There is potential that the observed reduction in mature miRNAs within this project, 
upon dual knockdown, could be due to disruption to both DICER efficiency and 
strand selection, including unloading of miRNA from DICER and preferential loading 
onto AGO. 
Both TRBP and PACT can influence strand selection and loading of miRs from DICER 
to Argonaute (Wilson et al., 2015; Noland and Doudna, 2013). The mechanism of this 
action, utilising the flexibility of unstructured linker regions between domains 
(Heyam et al., 2015), may also suggest that these proteins have the potential to boost 
efficiency in moving miRs from DICER to AGO. 
MiRNAs are tightly associated with RISC complexes, with less than 3% of total 
miRNAs ‘free’ within the cytoplasm (Tang et al., 2008). It is therefore argued that a 
reduction in loading efficiency of miRNA onto Argonaute protein could also result in 
a reduction of ubiquitously expressed miRNAs. This may be due to ‘free’ or unbound 
miRNA being more available for degradation than those in complex with RISC. 
Therefore, disruption to both DICER processing efficiency and loading of argonaute 
could contribute to the reduction of ubiquitous miRNAs upon dual depletion of TRBP 
and PACT. 
However, using the data generated in this project, the most likely explanation for this 
reduction is that TRBP and PACT are redundant in the specific function of ensuring 
efficient DICER processing. This is not to say that they are redundant proteins overall, 
as it is already known that they have opposite effects on PKR (Singh et al., 2011) and 
only TRBP can alter bulge mismatches in pre-miRNA stems prior to DICER cleavage 
(Zhu et al., 2018). If this theory is correct, it could be that Homo sapiens have two 
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dsRBDs that can assist DICER cleavage of pre-miRNAs as these will produce mature 
miRNAs of different seed sequences and length, increasing diversity of mature 
miRNAs without the requirement of further transcripts from the nucleus.  
To elucidate the exact mechanisms of the synergistic downregulation of highly 
expressed miRs observed, we propose in vitro reconstitutions similar to that of Fareh 
et al. to determine if PACT has the capability to help DICER differentiate between 
cellular RNAs. Additionally, we propose in vitro reconstitution with DICER and 
Argonaute proteins, to determine whether TRBP and/or PACT assist strand loading 
onto Argonaute. This could be assessed through qPCR analysis following 
precipitation of protein-miRNA complexes similar to that described by Queiroz et al., 
2018. Furthermore, it would be beneficial to produce double knockout cell lines, to 
assess whether stable depletion of TRBP and PACT together result in dysregulation of 
microRNA biogenesis, or whether cells are indeed able to compensate for this loss of 
function over time. This would be compared to further knockdown experiments for a 
larger array of microRNAs, and could be conducted via deep sequencing or extensive 
qPCR experiments. DICER knockdown and knockouts would be completed in 
parallel. 
Overall, we disagree with Kim et al. (2014) that PACT does not play a role in miRNA 
biogenesis in HeLa cells and instead state that both TRBP and PACT have roles in the 
biogenesis pathway, at least in the three cancer lines utilised for this project. Our 
results identify a new finding in miRNA biogenesis, previously unseen due to dual 
depletion being less widely reported in literature. Further to this, when dual 
depletion is observed, this is through a stable gene knockout, where we are currently 
unsure if cells have time to compensate for functional loss. 
A major limitation of this project is the lack of comparison of TRBP and PACT protein 
depletion to DICER protein depletion. Unfortunately, due to technical difficulties, we 
were unable to successfully detect DICER via western blot, though we were able to 
measure mRNA. Comparison to DICER knockdown would allow us to make more 
accurate predictions on the mechanistic effects of the DICER co-factors depletion, 
and whether these reflect reduced DICER processing or if there are further 
mechanisms of action in place. Though we were able to see a reduction of DICER 
mRNA after treatment with siRNA, we do not see any effects on highly expressed 
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canonical microRNAs. This suggests that DICER was not sufficiently reduced as to 
impair function.  
However, this may not be the only explanation for this observation. MicroRNAs are 
inherently stable from a few hours to a few weeks (review by Zhang et al., 2013). 
Knockdown experiments over 48 hours may not constitute enough time for the 
measured microRNAs to diminish significantly due to lack of further biogenesis. 
However, this argument would suggest that dual TRBP and PACT depletion was 
somehow reducing microRNA levels rather than disrupting the formation of new 
mature RNA strands. Therefore, we suggest the most likely option that DICER 
depletion was not sufficient. 
4.2 TRBP and PACT interact endogenously 
During this project, we hypothesised that TRBP and PACT interact endogenously in 
human cell lines; interaction has already been identified in vitro and with transfected 
tagged proteins in mammalian cells (Singh et al., 2011; Laraki et al., 2008). We 
hypothesised that interaction may vary between different cell lines and cell types.  
We confirm that TRBP and PACT bind one another in human cell lines and suggest 
that these complexes form heterodimers. This is because both TRBP and PACT 
interact with other proteins via the same domain, particularly binding DICER and 
each other with the same interface (Heyam et al., 2017). Binding of DICER is through 
mutual exclusion, meaning that both TRBP and PACT cannot be in complex with 
DICER at one time (Wilson et al., 2015). These two papers are in disagreement with 
an earlier study by Kok et al., (2007), which suggested that human TRBP, PACT and 
DICER and form a ternary complex. Data provided by Kok et al., (2007), in the form 
of immunoprecipitation assays, does not confirm that all three proteins are in one 
complex, but instead that they can all interact, and this may be by mutual exclusion 
as suggested by Wilson et al., (2015). 
However, this does not exclude the possibility that both TRBP and PACT could 
simultaneously bind further proteins or substrates with multiple binding sites, such 
as RNA. TRBP domains 1 and 2 can simultaneously bind one siRNA strand at different 
sites (Masliah et al., 2018). With the similar structure and sequence of TRBP and 
PACT domains 1 and 2, this may suggest that TRBP and PACT could mutually bind a 
singular RNA, though this would require experimental confirmation. This also opens 
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up the possibility that complex interactions, such as that with PKR could also have an 
intermediary substrate such as RNA.  
TRBP and PACT have previously been identified to form heterodimers when 
transfected within HeLa cells (Laraki et al., 2008); we confirm that this happens 
naturally without overexpression of either co-factor or adjustment of PKR pathways. 
Protein-protein interactions occur for a variety of reasons including to enable 
performance of a function, to regulate another protein and for stability. There is 
potential that TRBP and PACT could interact for any of the above reasons. 
Contrary to expectations proposed in 3.5, MDA-MB-231 presented with the lowest 
level of PACT co-IP, whilst RCC4 displayed the highest level. This could suggest that 
cells with a higher interaction have a surplus of protein: both TRBP and PACT bind 
DICER, with TRBP demonstrating enhanced levels of DICER binding over PACT 
(Wilson et al., 2015). If TRBP and PACT have a higher level of interaction over TRBP-
DICER, it could be due to a surplus of requirement in the cell, i.e. the co-factors are 
not functionally required and have bound each other for stability. This theory would 
support our results, indicating that cells with surplus of DICER co-factors show less 
disruption to miRNA biogenesis during depletion of TRBP and PACT. 
However, if we factor in the percentage IP of TRBP, levels of interaction between 
TRBP and PACT are actually very similar between the renal and breast cancer cell 
lines. For that reason, it is unlikely that the mild variation in miRNA and PD-L1 
expression observed between cell lines upon depletion of TRBP and PACT are due to 
the molecular interactions of the DICER co-factors. We therefore conclude that this 
assay indicates no significant differences in the interaction of TRBP and PACT 
between the different cell lines. 
Previous literature suggests that TRBP and PACT may interact as a mechanism of 
regulation. For example, binding of PACT to TRBP reduces association with PKR, and 
by weakening this interaction, PACT’s ability to activate PKR is significantly 
enhanced (Singh et al., 2011). There is potential that although TRBP and PACT do not 
regulate each other on a protein level, they may regulate each other’s activity across 
distinct pathways such as the stress response – i.e. where TRBP may bind PACT to 
prevent activation of PKR. This is not something we observed in this project, however 
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we would not expect to see a change in protein levels in this circumstance, unless 
PACT was overexpressed and TRBP may become upregulated to combat this. 
The co-immunoprecipitation itself was limited in interpretation due to several 
drawbacks. This includes ‘miscellaneous’ black dots present after probing for TRBP, 
which hindered quantification of samples. Further to this we did not achieve high 
levels of TRBP pulldown, with the highest precipitation predicted to be around 18% of 
the input. Suggestions for improvement here could involve using antibody and bead 
slurry in excess and increasing incubation periods to ensure maximum binding 
events. 
Finally, although a confirmation antibody was used between primary and secondary 
antibodies, we still observed bands for the heavy and light chains of the IgG and 
TRBP antibodies used to pull down the respective proteins. A conformation antibody 
will be of a different species to the original antibody used to pull down protein, in 
order to reduce the noise of heavy and light chains remaining in the precipitate. The 
heavy chain of these antibodies may be partially obscuring some of the TRBP band, 
and again hindered quantification. Ideally, this assay would be further optimised and 
then repeated to ensure reproducibility.  
In summary, we identify endogenous interactions between TRBP and PACT across 
three human cancer cell lines but cannot confirm if interaction differs between these. 
We suggest that TRBP and PACT may interact for protein stability, regulation, or dual 
functionality, though the exact purpose remains unclear at the current time. 
4.3 Depletion of PACT within breast cancer cells results in upregulation 
of PD-L1 
In section 1 it is suggested that dysregulation of microRNA biogenesis may be linked 
to immunity through dsRNA stress; PKR is activated by median levels of double-
stranded RNA and PACT, but inhibited by high levels of double-stranded RNA and 
TRBP. Upon dsRNA stimulation, such as might be caused by dysregulated microRNA 
biogenesis, PKR is activated and may lead to apoptosis through translational 
inhibition (Gil and Estabon, 2000). We suggested that dysregulation to miRNA 
biogenesis through disruption of co-factors TRBP and PACT may result in dsRNA 
stress, PKR activation and increased PD-L1 expression.  
Upon depletion of PACT within breast cancer cells, we observed, on average, a 2-fold 
increase in PD-L1 expression. Reduction of TRBP did not affect PD-L1 expression and 
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depletion of both DICER co-factors did not illicit an enhanced response. Therefore, it 
is suggested that PD-L1 upregulation is not in response to dsRNA stress caused by a 
reduction in miRNA processing as first hypothesised. Rather, we propose cross-talk 
between miRNA biogenesis and the stress response through PACTs interaction with 
PKR, and thus a novel immunological function of PACT. 
PACT is an activator of PKR, which actively self phosphorylates upon stimulation. In 
turn, activated PKR can phosphorylate eIF2α; phosphorylation of eIF2α inhibits 
general protein translation (Krishnamoorthy et al., 2001; Deng et al., 2004; Hershey et 
al., 2012, Singh and Patel, 2012). Therefore, it is logical to suggest that depletion of 
PACT may reduce phosphorylation of PKR, eIF2α and reduce the regulation of 
translation (depicted schematically in figure 24).  
A reduction in translation regulation may lead to increased rates of translation, hence 
an increase in protein production as seen for PD-L1 and STAT1 in MDA231 cell lines. 
However, this would suggest a general upregulation in protein, and analysis was 
normalised to housekeeping proteins such as GAPDH and β-actin. Therefore, what 
we are seeing is either only an upregulation of STAT1 and PD-L1, or a greater 
upregulation of these two proteins in relation to β-actin.  
To test this theory, activation of PKR could be assessed via western blot, probing for 
phosphorylated-PKR against total PKR. Phosphorylation of eIF2α could also be 
assessed to this extent, with the option of conducting plate-based assays utilising 
antibodies against total and phosphorylated eIF2α in the same step (example: 
64EF2PEG Phospho-EIF2 alpha (Ser52) cellular kit by Cisbio, link in appendix 6.2). 
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It should be noted here that PKR and STAT1 also have direct interactions, though 
PKR does not actively phosphorylate STAT1 (Wong et al., 1997) and does not need to 
be activated in order to bind. Interaction occurs with the dsRBD on PKR (Wong et al., 
1997), the same surface that binds with PACT, and leads to prevention of STAT1 
phosphorylation (Ramana et al., 2000). Depletion of PACT reduces PKR-PACT 
interaction, increasing the likelihood of PKR-STAT1 interaction, preventing 
phosphorylation to PSTAT1. This may contribute to the upregulation of STAT1 
observed in this project upon PACT depletion in MDA231 cells. 
Limitations of this finding include establishing if PD-L1 upregulation is functionally 
significant. Targeting of mRNA transcripts may not directly affect mRNA abundance, 
as binding of the RISC may result in prevention of translation rather than mRNA 
cleavage (see section 1.1). Though from this study we can say that PD-L1 protein is 
upregulated upon transient knockdown of PACT in MDA-MB-231 cells, we cannot 
certify that this is functionally significant, i.e. whether this would affect T cell 
activation or other cellular interactions. Confirmation of functionality could be 
assessed by flow cytometry, i.e. assessing that increased levels of protein are indeed 
being expressed on the cell surface. Alternatively, we suggest co-culturing PACT 
depleted cells with activated T cells and measuring sustained T cell activation 
through an IL-2 ELISA as previously demonstrated by Yee (2018). IL-2 is a 
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proinflammatory interleukin released by T cells to promote propagation and an 
inflammatory response (Hoyer et al., 2008). 
 At the current time, the role of PACT in PD-L1 regulation remains uncertain. We 
only identify a significant change in breast cancer cells, with the possibility that this 
could be specific to this cell type. We propose expanding the current results through 
depletion or overexpression of PKR to determine if change in PD-L1 expression is via 
the stress response or other unknown pathway.  
Alternatively, if this line of enquiry yields no results, it is possible that depletion of 
PACT alone can lead to downregulation of specific miRNAs, as yet unknown, that can 
regulate both PD-L1 and/or STAT1. This could be investigated through miRNA 
sequencing, after PACT knockdown and/or knockout. 
4.4 Future Work 
In summary, to progress from these findings, we propose confirmation of PACT’s 
ability to aid loading of substrates to DICER. We also suggest comparison of transient 
knockdown to stable knockout of both TRBP and PACT in a variety of different cell 
types, in order to investigate if cells compensate for the loss of co-factors over time. 
Finally, we propose a parallel analysis with DICER depletion, to identify if depletion 
of TRBP and PACT are a reflection of DICER processing disruption. 
In regard to the role of PACT in PD-L1 expression, we propose that further breast 
cancer cell lines could be examined in collaboration with PKR depletion or 
overexpression experiments. 
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5. Conclusion 
This project aimed to investigate the dsRBPs TRBP and PACT in relation to their roles 
in microRNA biogenesis and novel functions within immunity. We conclude that 
both TRBP and PACT participate in the regulation of mature microRNAs contrary to 
previous publications. We reveal a novel finding, that only upon depletion of both 
DICER co-factors is abundance of selected mature microRNAs significantly reduced. 
We also reveal a novel role of PACT in the expression of immune checkpoint PD-L1 in 
non-IFN-γ-stimulated environments, with the suggestion that this is through 
interaction with PKR and the stress response.  
Finally, we confirm the endogenous interaction of TRBP and PACT within HeLa, 
RCC4 and MDA-MB-231 human cell lines.  
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6. Appendices 
6.1 Solutions made in house 
Solution Reagents 
4x Sample buffer 250nM Tris HCL pH 6.8 
8% (w/v) SDS 
10% (w/v) Glycerol 
5% (v/v) β-Mercaptoethanol 
0.05% (w/v) Bromophenol Blue 
 
RIPA (100mL) 150mM / 0.876g NaCl 
10mM / 1mL 1M Tris-HCl (pH 7.2) 
0.1% / 1mL 10% w/v SDS 
0.1% / 100µL Triton X-100 
1% / 1g Sodium Deoxycholate 
5mM / 1mL 0.5M EDTA 
 
10x TBS 1L ddH2O 
12.2g Tris HCl 
87.65g NaCl 
pH 8.0 
 
TBST 900mL dd H2O 
100mL 10x TBS 
1mL Tween 20 
 
Freeze media 10% (v/v) DMSO 
90% (v/v) FCS 
 
Stacking gel (5%) 4.1mL     H2O 
1.0mL     30% Acrylamide mix 
0.75mL   1.5M Tris (pH 6.8) 
0.06mL   10% SDS 
0.06mL   10% Ammonium persulfate 
0.006mL TEMED  
 
 
ii 
 
Resolving gel (10%) 4.0mL     H2O 
3.3mL     30% Acrylamide mix 
2.5mL     1.5M Tris (pH 8.8) 
0.1mL     10% SDS 
0.1mL     10% Ammonium persulfate 
0.004mL TEMED 
 
FACS buffer 1L PBS 
0.05% Azide 
1% FCS 
 
SOC media 2% tryptone 
0.5% yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose 
 
LB Broth (1L) 1L ddH2O 
10g Tryptone 
5g Yeast Extract 
10g NaCl 
pH 7.5 
 
(+/-) 1mL Ampicillin (100mg/ml) 
 
Agar (1L) 1L dd H2O 
10g Tryptone 
5g Yeast Extract 
10g NaCl 
pH 7.5 
15g Agar 
 
(+/-) 1mL Ampicillin (100mg/ml) 
 
Table 6: Solutions  
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6.2 Product links 
64EF2PEG Phospho-EIF2 alpha (Ser52) cellular kit by Cisbio 
https://www.cisbio.eu/phospho-eif2-alpha-ser52-cellular-kit-40562 [Accessed 11.04.19] 
 
Abbreviations List 
AGO: Argonaute 
BCA: bicinchoninic acid  
BSA: bovine serum albumin 
CD: cluster of differentiation molecule e.g. CD274 
Co-IP: co-immunoprecipitation 
CT: cycle threshold 
DGCR8: DiGeorge syndrome critical region 8 
DMEM: Dulbecco’s modified Eagle’s Medium  
dsRBP: double-stranded RNA-binding protein 
dsRBD: double-stranded RNA-binding domain 
dsRNA: double-stranded RNA 
eIF2α: alpha unit of eukaryotic initiation factor 2 
FCS: Foetal calf serum 
GFP: green fluorescent protein  
IFN-γ: Interferon gamma 
IL: Interleukin 
IP: Immunoprecipitation 
MDA231: MDA-MB-231 
miRNA: microRNA 
mRNA: messenger RNA 
ncRNA: non-coding RNA 
NF-ĸB: nuclear factor kappa-light-chain-enhancer of activated B cells 
nt: nucleotide 
NTC: non-targeting control 
PACT: Protein Activator of PKR 
iv 
 
PBS: Phosphate buffered saline 
PD-L1: Programmed Death Ligand 1 
PKR: Protein Kinase R 
Pre-miRNA: precursor microRNA 
Pri-miRNA: primary microRNA 
RIPA: radioimmunoprecipitation assay  
RISC: RNA induced silencing complex 
RNAi: RNA interference 
siRNA: short interfering RNA 
TBST: tris-buffered saline with tween 
TRBP: transactivation response (TAR) RNA-binding protein 
tRNA: transfer RNA 
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